## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -5.0% below STRENGTH zone (4.0-10.0%); PEG 1.97 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-9.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($190.41)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Cardinal Health (CAH) Stock Pulls Back From Record Highs: Latest News, Forecasts and Investment Outlook as of December 3, 2025**
- Source: ts2.tech | 20251203T230739 | Somewhat-Bullish | Relevance: 100%
- Cardinal Health (CAH) stock has experienced a pullback after a significant rally in 2025, with shares down 2.64% on December 3, 2025. Despite this recent weakness, the company has delivered strong year-to-date returns and robust Q1 FY 2026 results, driven by specialty pharmaceuticals and strategic acquisitions like Solaris Health. Analyst sentiment remains largely positive with "Buy" ratings and target price increases, though valuation concerns and execution risks are noted by more cautious investors, suggesting a potential consolidation phase for the stock.

**2. Key facts: Cardinal Health prioritizes high ROI; officers surrender shares**
- Source: TradingView | 20251203T210623 | Somewhat-Bullish | Relevance: 100%
- Cardinal Health (CAH) focuses its capital deployment strategy on high return on investment opportunities, emphasizing shareholder returns and strategic mergers and acquisitions. Recently, on December 2, 2025, company officers surrendered 1,949 shares to cover costs associated with exercising options and tax liabilities, as reported to the SEC.

**3. What Recent Specialty Pharma Moves Mean for Cardinal Healthâ€™s Stock Valuation**
- Source: Sahm | 20251203T111142 | Somewhat-Bullish | Relevance: 100%
- Cardinal Health's stock has seen significant growth, climbing 76.2% year-to-date, driven by its expansion into specialty pharmaceuticals and distribution partnerships. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 55%, its current Price-to-Earnings (PE) ratio of 31x is slightly above its fair level of 29.4x, indicating that the valuation is "about right" given its financial profile and future potential. The article encourages investors to use "Narratives" to customize valuation models based on their own assumptions about the company's future.

**4. CAH SEC Filings - Cardinal Health Inc 10-K, 10-Q, 8-K Forms**
- Source: Stock Titan | 20251201T182131 | Somewhat-Bearish | Relevance: 100%
- This page provides an overview of Cardinal Health (CAH) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-powered summaries and real-time alerts for insider transactions. Recent filings detail performance-based share awards to key executives, a Form S-3 shelf prospectus, and fiscal year 2025 financial results showing increased operating earnings despite a revenue dip. The company also announced an acquisition and year-end results reporting.

**5. West Family Investments Inc. Makes New Investment in Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251203T021032 | Bullish | Relevance: 100%
- West Family Investments Inc. acquired a new stake in Cardinal Health (NYSE:CAH) during Q2, purchasing 1,793 shares valued at approximately $301,000. Cardinal Health exceeded Q2 earnings expectations with $2.55 EPS and $64.01 billion revenue, and issued optimistic FY2026 EPS guidance. Institutional ownership remains high at 87.17%, with analysts generally holding a "Moderate Buy" consensus and an average price target of $206.57.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-05 | Wells Fargo | $221 | $185 | +19% |
| 2025-11-04 | Mizuho | $210 | $170 | +24% |
| 2025-11-03 | TD Cowen | $225 | $183 | +23% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-05 | Wells Fargo | main | Overweight |
| 2025-11-04 | Mizuho | main | Outperform |
| 2025-11-03 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-9.1% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +22%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.97 elevated, pricing in significant growth expectations. Analyst sentiment positive (3 raises, avg +22%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $49.5B |
| Beta | 0.64 |
| 52W Range | $117.53 - $214.93 |
| Short Interest | 2.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.97 |
| Forward P/E | 18.0 |
| Current P/E | 20.3 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.1% to -5.0% (-9.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.0pp (needs >4.0% for momentum thesis). AM_20 at -3.2% indicates price below own 20MA trend. Underperforming sector by 4.8pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.29x) but short-term weakness (below SMA20). MACD histogram bearish (-2.36), momentum weakening. RSI neutral at 53. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -MTH (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.02% (CS: 9) | Weak |
| RSI_14 | 53.2 | Neutral |
| MACD Histogram | -2.36 | Bearish |
| vs SMA20 | 0.968x | Below |
| vs SMA50 | 1.112x | Above |
| vs SMA200 | 1.286x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $199.71
- **Stop Loss:** $190.41 (4.7% risk)
- **Target:** $209.01 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 102
- **Position Value:** $20,370.42
- **Portfolio %:** 20.37%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*